Modulators of dopamine neurotransmission

US6924374B2 · kind B2 · utility

Assignee

• A. CARLSSON RESEARCH AB · SE

Inventors

• Bengt R. Andersson · Göteborg, SE
• Susanna Waters · Handen, SE
• Nicholas Waters · Handen, SE
• Joakim Tedroff · Danderyd, SE
• Clas Sonesson · Lindome, SE

Key dates

• Filing date: Dec 22, 2000
• Grant date: Aug 2, 2005
• Expiry date: Dec 22, 2020

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D295/096
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

New 3-substituted 4-(phenyl-N-alkyl)-piperazine and 4-(phenyl-N-alkyl)-piperidine compounds of Formula (1) wherein X is N, CH, or C, however X may only be C when the compound comprises a double bind at the dotted line; R1 is CF3, OSO2CF3, OSO2CH3, SOR7, SO2R7, COR7, CN, OR3, NO2, CONHR3, 3-thiophene, 2-thiophene, 3-furane, 2-furane, F, Cl, Br, or I; R2 is F, Cl, Br, I, CN, CF3, CH3, OCH3, OH, and NH2; R3 and R4 are independently H or a C1-C4 alkyl; R5 is a C1-C4 alkyl, an allyl, CH2SCH3, CH2CH2OCH3, CH2CH2CH2F, CH2CF3, 3,3,3-trifluoropropyl, 4,4,4-trifluorobutyl, or —(CH2)R6; R6 is a C3-C6 cycloalkyl, 2-tetrahydrofurane, or 3-tetra-hydrofurane; R7 is a C1-C3 alkyl, CF3, or N(R4)2, and pharmaceutically acceptable salts thereof are disclosed. Also pharmaceutical compositions comprising the above compounds and methods wherein the above compounds are used for treatment of disorders in the central nervous system are disclosed.